These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38222740)

  • 21. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
    Galsky MD; Hahn NM; Powles T; Hellerstedt BA; Lerner SP; Gardner TA; Yu M; O'Rourke M; Vogelzang NJ; Kocs D; McKenney SA; Melnyk AM; Hutson TE; Rauch M; Wang Y; Asmar L; Sonpavde G
    Clin Genitourin Cancer; 2013 Jun; 11(2):175-81. PubMed ID: 23228446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.
    Aydin AM; Cheriyan SK; Reich R; Hajiran A; Peyton CC; Zemp L; Yu A; Li R; Poch MA; Spiess PE; Jain R; Zhang J; Sexton WJ; Gilbert SM
    Urol Oncol; 2022 Oct; 40(10):453.e19-453.e26. PubMed ID: 35811208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
    Baras AS; Gandhi N; Munari E; Faraj S; Shultz L; Marchionni L; Schoenberg M; Hahn N; Hoque MO; Berman D; Bivalacqua TJ; Netto G
    PLoS One; 2015; 10(7):e0131245. PubMed ID: 26230923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
    Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF
    J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience.
    Iyer G; Tully CM; Zabor EC; Bochner BH; Dalbagni G; Herr HW; Donat SM; Russo P; Ostrovnaya I; Regazzi AM; Milowsky MI; Rosenberg JE; Bajorin DF
    Clin Genitourin Cancer; 2020 Oct; 18(5):387-394. PubMed ID: 32273235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
    Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
    World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
    Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
    Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
    Grivas PD; Hussain M; Hafez K; Daignault-Newton S; Wood D; Lee CT; Weizer A; Montie JE; Hollenbeck B; Montgomery JS; Alva A; Smith DC
    Urology; 2013 Jul; 82(1):111-7. PubMed ID: 23706253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
    Martinez Chanza N; Soukane L; Barthelemy P; Carnot A; Gil T; Casert V; Vanhaudenarde V; Sautois B; Staudacher L; Van den Brande J; Culine S; Seront E; Gizzi M; Albisinni S; Tricard T; Fantoni JC; Paesmans M; Caparica R; Roumeguere T; Awada A
    BMC Cancer; 2021 Dec; 21(1):1292. PubMed ID: 34856936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study.
    Ren X; Tian Y; Wang Z; Wang J; Li X; Yin Y; Chen R; Zhan Y; Zeng X
    BMC Urol; 2022 Aug; 22(1):128. PubMed ID: 35987640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities.
    Ruplin AT; Spengler AMZ; Montgomery RB; Wright JL
    Clin Genitourin Cancer; 2020 Oct; 18(5):e557-e562. PubMed ID: 32201105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
    van de Putte EE; Mertens LS; Meijer RP; van der Heijden MS; Bex A; van der Poel HG; Kerst JM; Bergman AM; Horenblas S; van Rhijn BW
    World J Urol; 2016 Feb; 34(2):157-62. PubMed ID: 26184106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
    Daneshmand S; Brummelhuis ISG; Pohar KS; Steinberg GD; Aron M; Cutie CJ; Keegan KA; Maffeo JC; Reynolds DL; Raybold B; Chau A; Witjes JA
    Urol Oncol; 2022 Jul; 40(7):344.e1-344.e9. PubMed ID: 35431132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial.
    Yuk HD; Jeong CW; Kwak C; Kim H; Moon KC; Ku JH
    BMJ Open; 2020 Oct; 10(10):e035530. PubMed ID: 33060077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma.
    Du Z; Yin H; Zhao S; Ma Y; Sun Z; Dong B; Zhu M; Zhu C; Peng J; Yang T
    Front Oncol; 2022; 12():1062655. PubMed ID: 36620538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
    Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T
    Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.
    Pal SK; Ruel NH; Wilson TG; Yuh BE
    Clin Genitourin Cancer; 2012 Dec; 10(4):246-50. PubMed ID: 22981208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience.
    El-Gehani F; North S; Ghosh S; Venner P
    Can Urol Assoc J; 2014 Mar; 8(3-4):e287-93. PubMed ID: 24839503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.